CSF3 and stroke disorder: Tsai and colleagues presented successful results of their clinical trials, demonstrating granulocyte colony-stimulating factor (GCSF) administration, as well as bone marrow mesenchymal stem cells (MSCs) (CD34+) mobilized by GCSF in stroke treatment.